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Mutation of a common amino acid in
NKX2.5 results in dilated cardiomyopathy
in two large families
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Abstract
Background: The genetic basis for dilated cardiomyopathy (DCM) can be difficult to determine, particularly in
familial cases with complex phenotypes. Next generation sequencing may be useful in the management of such
cases.
Methods: We report two large families with pleiotropic inherited cardiomyopathy. In addition to DCM, the
phenotypes included atrial and ventricular septal defects, cardiac arrhythmia and sudden death. Probands
underwent whole exome sequencing to identify potentially causative variants.
Results: Each whole exome sequence yielded over 18,000 variants. We identified distinct mutations affecting a
common amino acid in NKX2.5. Segregation analysis of the families support the pathogenic role of these variants.
Conclusion: Our study emphasizes the utility of next generation sequencing in identifying causative mutations in
complex inherited cardiac disease. We also report a novel pathogenic NKX2.5 mutation.
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Background
Dilated cardiomyopathy (DCM) is a condition associated
with significant morbidity and mortality that may have
identifiable causes or may be idiopathic or inherited. A
spectrum of genetic loci associated with DCM has been
identified, with over 30 genes implicated [1].
We sought to identify the causative mutation in two
unrelated individuals with DCM. Each reported an
extensive family history of congenital heart disease
(CHD) with multiple cardiac diagnoses affecting several
family members. In addition to identifying potential
causative mutations, we also sought to address the possi-
bility of a founder effect as both families lived in the
same rural geographic area.
To accomplish these goals, we took advantage of the
increasing availability and rapidly decreasing cost of next
generation sequencing to identify variations within the
protein coding region of the genome. We describe the
identification of variants potentially implicated in the
cardiac disease affecting both families. We also provide a
description of our approach to prioritizing variants for
further segregation analysis, and the subsequent discovery
of a novel NKX2-5 variant.
Case presentations
A female in her early forties (family 186) presented
acutely to hospital with pulmonary edema, atrial fibrilla-
tion and non-sustained ventricular tachycardia (VT).
She had no prior history of cardiac disease. Echocardiog-
raphy demonstrated severely impaired left ventricular
function. Her son and father had both undergone pace-
maker implantation at the age of fifteen and in the
fourth decade of life respectively. In addition, there was
a history of cardiac disease in the extended family in-
cluding DCM, atrial and ventricular septal defects and
sudden death (Fig 1, Table 1).
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A second unrelated proband (family 187) presented to
the same practice in her teenage years with DCM and
VT treated with an implantable cardioverter-
defibrillator. She also had severely impaired left ventricu-
lar function as demonstrated on echocardiography.
Family history was remarkable for cardiac disease in-
cluding DCM, atrial and ventricular septal defects and
sudden death (Fig 2, Table 2).
Both families lived in adjacent rural towns with popu-
lations of approximately 11,600 and 1,650 people,
respectively. Due to the similarities in phenotypes and
small referral population we suspected a founder effect
may be present, with a common mutation accounting
for the observed illnesses. The families were unable to
identify a common ancestor, despite well-documented
pedigrees extending to the mid-nineteenth century.
Ethics approval and consent to participate
All participants were enrolled in the ongoing genetics of
cardiovascular disease study at Massachusetts General
Hospital (MGH). The study was approved by the Institu-
tional Review Board and Human Research Committee at
Fig. 1 Pedigree showing affected and unaffected individuals in family 186. Alignment chromatograms showing representative wildtype
(WT, above) and heterozygous mutant (I184F, below) tracings
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MGH and complied with the Declaration of Helsinki.
Written informed consent, including consent to publish
was obtained prior to performing the evaluations. The
probands agreed to genetic testing by way of next gener-
ation sequencing in an effort to identify a causative mu-
tation. Samples were processed with the Roche Large
Volume DNA isolation kit using magnetic bead technol-
ogy, following which genomic DNA was extracted on
the Roche MagnaPure Automated DNA extractor.
Methods
Exome capture was performed using Agilent SureSelect
assay (v4) according to the manufacturer’s recommenda-
tion. The library was then amplified and pair-end
sequenced by the Illumina HiSeq 2500 platform at the
Broad Institute (Cambridge, MA). The BWA software
package (Version: 0.5.8) was used to map the sequenced
reads to the human reference genome (NCBI Build 37,
Fig. 2 Pedigree showing affected and unaffected individuals in family 187. Alignment chromatograms showing representative wildtype
(WT, above) and heterozygous mutant (I184M, below) tracings
Table 1 Clinical characteristics of family 186
Pedigree Genotype Clinical data
V1 + CHB, PPM, ASD
V2 + 1st degree AVB








III.5 NA DCM, VT
IV.6 NA ASD, SCD
III.6 NA DCM, AF, SCD
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hg19) [2]. The resulted SAM files were then converted into
BAM files by samtools (Version: 0.1.18) [3]. The MarkDu-
plicates function of the Picard software package was used
to remove duplicate reads, which were defined as those
with the exact same start and end positions. The GATK
software package (Version 1.2–21) was used to recalibrate
base qualities and perform local realignment around indels.
The variant calling was implemented by the UnifiedGen-
otyper function within GATK software package [4].
Sequencing identified in excess of 18,000 variants in each
exome. Filtration and prioritization of the variants was per-
formed according to previously published methods [5]. First,
all common variants (>1%) identified in publically available
databases (dbSNP [6], 1000 Genomes Project [7],and Exome
Variant Server [8]) were removed from further analyses.
Second, synonymous variants were excluded on the basis
that these would have no effect on protein function. Follow-
ing this, analysis of evolutionary conservation of the altered
amino acids was performed using the Phylop tool.
PolyPhen-2, and SNAP were used to predict the effect of
the amino acid substitution on protein structure. Variants
affecting amino acids that are highly conserved through
evolution and those predicted to have a significant effect on
protein structure were then initially analyzed based on their
known association with human disease.
Results
An initial review of the observed variants revealed distinct
missense heterozygous mutations in NKX2.5 affecting the
same residue in both families. These variants were chosen
for further study due to the known role that mutations in
NKX2.5 play in inherited cardiovascular disease in humans.
None of the other variants had such a clear, previously
identified association with the observed phenotypes.
The residue, Isoleucine184, is found in the important
homeodomain region and is highly conserved. The
variant affecting family 186 was novel, affecting an
alignment site with a Phylop conservation score of 4.5
and leading to the amino acid substitution I184F. This
variant is predicted by Polyphen-2 to be probably dam-
aging with a score of 1. Exome variant analysis in family
187 revealed a mutation at a site with a Phylop conser-
vation score of 1.4, leading to the substitution I184M.
The Polyphen score was also 1, with a high probability
of being damaging. This variant has been previously
described in a family with DCM, left ventricular non-
compaction, atrial and ventricular septal defects and
conduction system disease [9]. Investigation of the func-
tional effect of this substitution revealed impaired DNA
binding with lowered transcriptional activity.
Following identification of these potentially pathogenic
mutations in the probands, extended family members under-
went clinical evaluation and PCR-based genotyping. Seven-
teen members of family 186 and nine members of family
187 underwent a standardized interview and physical exam-
ination. 12-lead electrocardiogram and echocardiogram were
performed where clinically indicated, or in case of a muta-
tion being identified. Affected individuals were identified as
those with a self-reported history of cardiac disease such as
septal defect closure in infancy, conduction system or
rhythm abnormalities on the electrocardiogram or evidence
of septal defect or DCM during echocardiographic analysis.
Availability of data and materials
Disease variants discovered in the present study will be
uploaded to the Database of Genotypes and Phenotypes
(dbGaP), Bethesda (MD): National Center for Biotechnol-
ogy Information, National Library of Medicine. Available
from: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap
Confirmation sequencing
Sanger sequencing was used to confirm the presence of vari-
ants and to perform segregation analysis. Oligonucleotide
primers flanking the putative variants were designed using
genomic sequences from the UCSC Genome Browser (hg19
assembly). Standard conditions were used to perform PCR.
DNA sequencing was performed using the ABI PRISM dye
terminator method (Applied Biosystems, CA, USA).
Segregation analysis
In family 186, the proband is individual IV.1. Her sons
(V.1 and V.2) demonstrated evidence of cardiac disease.
V.1 had a history of conduction system disease requiring
pacemaker implant at the age of 15. At the screening
visit a septal defect was apparent on echocardiography,
with the atrial pacemaker lead crossing through it to the
left atrium. V.2 had first degree heart block evident on
12-lead ECG. In addition, individual IV.4 had a cardiac
septal defect repaired surgically in infancy. At the
screening visit he was found to be in atrial fibrillation,
with mildly impaired LV function on echo. All of these
Table 2 Clinical characteristics of family 187
Pedigree Genotype Clinical data
III.2 + DCM





II.3 NA PPM, SCD
II.5 NA SCD, CAD
II.7 NA Tricuspid atresia, right ventricular
hypoplasia, PS, VSD
II.10 NA Cyanotic heart disease, SCD
III.3 NA SCD
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affected individuals were found to carry the I184F vari-
ant. Other individuals (IV.3, IV.5) harboring the muta-
tion had normal cardiac investigations, despite being
older than other clinically affected carriers, indicating
incomplete penetrance. Individual IV.4 had two young
children (not shown) who are also carriers without
evidence of disease, possibly due to their young age.
Several affected individuals were unavailable for genetic
testing. Specifically, the proband’s father, III.2 had a pace-
maker implanted while in his fourth decade. His brother,
III.3 also had a pacemaker. A paternal great-uncle, II.3,
had a pacemaker and his daughter, III.4, suffered sudden
death at the age of nineteen. Individual II.6 died suddenly
at age 3. III.5 was diagnosed with DCM and VT. His
daughter, IV.6 had an atrial septal defect and died sud-
denly at the age of 15. Her paternal uncle, III.6 had DCM
and AF, and died suddenly aged 51.
In family 187, the proband is individual III.1. Her sister
(III.2) was diagnosed with DCM just prior to enrollment.
A first-degree cousin, III.4, had a history of DCM requir-
ing transplantation. His daughter (IV.1) had a septal
defect corrected surgically in infancy. These affected
individuals were all carriers of the I184M variant. Other
members of the pedigree had cardiac disease but did not
carry the variant. Individual III.6 had a history of non-
sustained polymorphic VT documented on 24 hour
Holter monitor. This may have been related to extreme
caffeine intake at the time of the recording. Her father
who died suddenly at a young age (II.5) had documented
coronary disease at post mortem examination which was
listed as the cause of death. Individual III.9 has a
ventricular septal defect, despite not carrying the muta-
tion. As her parents are mutation negative and are both
healthy, it is probable that this is a sporadic phenomenon.
Some affected individuals were unavailable for genetic
testing; the proband’s father (II.1) had a cardiac device
implanted. His death was non-cardiac. His brother, II.3
had a pacemaker implanted aged 33 and died suddenly.
His sister, II.7 had complex congenital cardiac disease in-
cluding tricuspid atresia, right ventricular hypoplasia, pul-
monary stenosis and a ventricular septal defect requiring a
bidirectional Glenn shunt. Individual II.10 had cyanosis
and died suddenly in infancy. Another sibling (not shown)
was stillborn. Individual III.3 died suddenly aged 22.
Discussion
NKX2.5 is a highly conserved homeobox transcription
factor that has a crucial role in cardiac development and
homeostasis, specifying critical elements such as tropo-
nin T, connexin 43, β-myosin heavy chain and myosin
light chain-2 [10, 11]. The gene is located on chromo-
some 5q34, spanning 2 exons and encoding a 324 amino
acid homeodomain-containing protein [12]. Mutations
in this gene cause a phenotypically broad array of
structural cardiac defects and arrhythmias with variable
penetrance [13]. The most common of these include sep-
tal defects and conduction system disease, supported by a
recent review of reported mutations [14–16]. While we
observed these phenotypes among families 186 and 187,
the index cases presented with dilated cardiomyopathy.
This was also the most common diagnosis among the ex-
tended pedigrees. We also observed incomplete pene-
trance, the cause for which is poorly understood but may
relate to maternal factors [17].
On the basis of the conservation score, expression pro-
file, predicted effect on protein function and segregation
with disease in the families, I184F-NKX2.5 and I184M-
NKX2.5 represent compelling candidate variants for the
broad spectrum of cardiac disease in families 186 and 187
respectively. Previously reported functional studies
provide further evidence to support the role of variants in
I184-NKX2.5 in congenital cardiac disease [9].
The management of families with complex inherited
cardiac disease is particularly challenging. Clinical testing
can only diagnose mutation carriers expressing a clear
phenotype. As mutations in some genes-including
NKX2.5-may exert their effect in a time-dependent man-
ner, longitudinal screening of unaffected individuals may
be required [18]. Presentation may also include sudden
death, and in the absence of a genetic diagnosis it can be
difficult to identify at-risk individuals. An informative
genetic test may therefore facilitate targeted screening and
spare mutation negative individuals from unnecessary
follow up and investigation.
In terms of achieving a molecular diagnosis, the pleio-
tropic nature of the conditions affecting families 186 and
187 does not implicate a particular gene or set of genes.
The overall yield of genetic testing for cardiomyopathies
employing current panels is 50–60% in the best cases
(such as arrhythmogenic right ventricular cardiomyop-
athy, or familial hypertrophic cardiomyopathy [19–21]).
Often the yield is either significantly lower than 50% or
may be unknown [22]. The yield for testing in chan-
nelopathies is similarly unimpressive, with the lone
exception of long QT syndrome [22]. In addition,
NKX2.5 is not included in most commercially available
diagnostic gene panels for either cardiomyopathy or
channelopathy [23–25].
Relying on traditional diagnostic methods would there-
fore have failed to yield a genetic diagnosis in families 186
and 187. Next generation sequencing provides a rapid and
unbiased approach of evaluating the exome, greatly
expanding the scope of genes in which mutations can be
identified. This allowed identification of NKX2.5 variants
in each of our probands. Identification of these variants
had important diagnostic and management implications
for the extended family. The discovery facilitated cascade
screening and enabled us to both arrange appropriate
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surveillance for otherwise healthy mutation positive indi-
viduals, and conversely to reassure and discharge healthy
mutation negative individuals from the clinic.
It is a remarkable coincidence that two families living
so close to each other with such a rare inherited disease
did not share the same mutation, refuting our initial
suspicion that a founder mutation would be discovered.
An additional coincidence is the genomic proximity of
the variants found in each study family with distinct
mutations affecting not only the same rarely-implicated
gene but also the same residue.
Conclusion
Next generation sequencing and in silico variant
prioritization may allow for rapid identification of patho-
genic and novel mutations in complex pedigrees with
pleiotropic cardiac disease. I184F-NKX2.5 is a novel
variant associated with congenital heart disease.
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